Mirela Dobre1, Nicholas M Pajewski2, Srinivasan Beddhu3, Michel Chonchol4, Thomas H Hostetter1, Ping Li5, Mahboob Rahman1,6, Karen Servilla7, Daniel E Weiner8, Jackson T Wright1, Kalani L Raphael3. 1. Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA. 2. Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA. 3. Veterans Affairs Salt Lake City Healthcare System, University of Utah Health, Salt Lake City, UT, USA. 4. Renal Diseases and Hypertension, University of Colorado Denver Anschutz Medical Campus, Aurora, CO, USA. 5. VA Medical Center, George Washington University, Washington, DC, USA. 6. Division of Nephrology, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA. 7. Nephrology, New Mexico VA Health Care System, Albuquerque, NM, USA. 8. Medicine, Nephrology, Tufts Medical Center, Boston, MA, USA.
Abstract
BACKGROUND: Low serum bicarbonate level is associated with increased mortality, but its role as a predictor of cardiovascular disease (CVD) is unclear. This study evaluates the association between serum bicarbonate concentration and CVD and whether the effect of intensive blood pressure (BP) lowering on CVD outcomes is modified by serum bicarbonate level. METHODS: The Systolic Blood Pressure Intervention Trial (SPRINT) randomized participants to a systolic BP target <120 mmHg (intensive treatment) or <140 mmHg (standard treatment). The primary CVD outcome was a composite of nonfatal myocardial infarction (MI), acute coronary syndrome not resulting in MI, stroke, acute decompensated heart failure and CVD death. Cox proportional hazards models adjusted for demographic, clinical and laboratory characteristics were used to evaluate the association of interest in 9334 SPRINT participants (ClinicalTrials.gov: NCT01206062). RESULTS: Over a median follow-up of 3.33 years (interquartile range 2.87-3.87 years), 618 (6.6%) participants experienced a primary CVD outcome. Participants with serum bicarbonate <22 mEq/L had a significantly higher risk of the primary CVD outcome (hazard ratio 1.54; 95% confidence interval 1.11-2.14, P = 0.01), compared with participants with bicarbonate 22-26 mEq/L. The magnitude of the CVD risk reduction with intensive BP lowering was similar across bicarbonate strata (P-value for interaction = 0.97). CONCLUSIONS: In hypertensive individuals, serum bicarbonate level <22 mEq/L was associated with an increased CVD risk. The effect of intensive BP lowering on CVD outcomes was not modified by the serum bicarbonate level.
BACKGROUND: Low serum bicarbonate level is associated with increased mortality, but its role as a predictor of cardiovascular disease (CVD) is unclear. This study evaluates the association between serum bicarbonate concentration and CVD and whether the effect of intensive blood pressure (BP) lowering on CVD outcomes is modified by serum bicarbonate level. METHODS: The Systolic Blood Pressure Intervention Trial (SPRINT) randomized participants to a systolic BP target <120 mmHg (intensive treatment) or <140 mmHg (standard treatment). The primary CVD outcome was a composite of nonfatal myocardial infarction (MI), acute coronary syndrome not resulting in MI, stroke, acute decompensated heart failure and CVD death. Cox proportional hazards models adjusted for demographic, clinical and laboratory characteristics were used to evaluate the association of interest in 9334 SPRINT participants (ClinicalTrials.gov: NCT01206062). RESULTS: Over a median follow-up of 3.33 years (interquartile range 2.87-3.87 years), 618 (6.6%) participants experienced a primary CVD outcome. Participants with serum bicarbonate <22 mEq/L had a significantly higher risk of the primary CVD outcome (hazard ratio 1.54; 95% confidence interval 1.11-2.14, P = 0.01), compared with participants with bicarbonate 22-26 mEq/L. The magnitude of the CVD risk reduction with intensive BP lowering was similar across bicarbonate strata (P-value for interaction = 0.97). CONCLUSIONS: In hypertensive individuals, serum bicarbonate level <22 mEq/L was associated with an increased CVD risk. The effect of intensive BP lowering on CVD outcomes was not modified by the serum bicarbonate level.
Authors: Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; Stacey E Jolly; Edgard Wehbe; Rupesh Raina; James F Simon; Titte R Srinivas; Anil Jain; Martin J Schreiber; Joseph V Nally Journal: Clin J Am Soc Nephrol Date: 2011-09-01 Impact factor: 8.237
Authors: Mirela Dobre; Jason Roy; Kaixiang Tao; Amanda H Anderson; Nisha Bansal; Jing Chen; Rajat Deo; Paul Drawz; Harold I Feldman; L Lee Hamm; Thomas Hostetter; John W Kusek; Claudia Lora; Akinlolu O Ojo; Kumar Shrama; Mahboob Rahman Journal: Am J Nephrol Date: 2016-05-28 Impact factor: 3.754
Authors: Walter T Ambrosius; Kaycee M Sink; Capri G Foy; Dan R Berlowitz; Alfred K Cheung; William C Cushman; Lawrence J Fine; David C Goff; Karen C Johnson; Anthony A Killeen; Cora E Lewis; Suzanne Oparil; David M Reboussin; Michael V Rocco; Joni K Snyder; Jeff D Williamson; Jackson T Wright; Paul K Whelton Journal: Clin Trials Date: 2014-06-05 Impact factor: 2.486
Authors: Emelia J Benjamin; Salim S Virani; Clifton W Callaway; Alanna M Chamberlain; Alexander R Chang; Susan Cheng; Stephanie E Chiuve; Mary Cushman; Francesca N Delling; Rajat Deo; Sarah D de Ferranti; Jane F Ferguson; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Pamela L Lutsey; Jason S Mackey; David B Matchar; Kunihiro Matsushita; Michael E Mussolino; Khurram Nasir; Martin O'Flaherty; Latha P Palaniappan; Ambarish Pandey; Dilip K Pandey; Mathew J Reeves; Matthew D Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Uchechukwu K A Sampson; Gary M Satou; Svati H Shah; Nicole L Spartano; David L Tirschwell; Connie W Tsao; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2018-01-31 Impact factor: 29.690
Authors: Mirela Dobre; Wei Yang; Jing Chen; Paul Drawz; L Lee Hamm; Edward Horwitz; Thomas Hostetter; Bernard Jaar; Claudia M Lora; Lisa Nessel; Akinlolu Ojo; Julia Scialla; Susan Steigerwalt; Valerie Teal; Myles Wolf; Mahboob Rahman Journal: Am J Kidney Dis Date: 2013-03-13 Impact factor: 8.860
Authors: Mirela Dobre; Wei Yang; Qiang Pan; Lawrence Appel; Keith Bellovich; Jing Chen; Harold Feldman; Michael J Fischer; L L Ham; Thomas Hostetter; Bernard G Jaar; Radhakrishna R Kallem; Sylvia E Rosas; Julia J Scialla; Myles Wolf; Mahboob Rahman Journal: J Am Heart Assoc Date: 2015-04-20 Impact factor: 5.501